Molnupiravir para la enfermedad COVID-19
Lagevrio
Revisado por Sid DajaniÚltima actualización por Michael Stewart, MRPharmSÚltima actualización 15 dic 2024
Satisface las necesidades del paciente directrices editoriales
- DescargarDescargar
- Compartir
- Idioma
- Debate
Molnupiravir is given to adults aged over 18 years when they have tested positive for COVID-19 and have at least one risk factor for developing severe illness.
Treatment should be started as soon as possible after diagnosis and within the first five days of symptoms.
The most common side-effects are feeling sick (nausea) and diarrhoea.
En este artículo:
Seguir leyendo
About molnupiravir
Tipo de medicamento | Antiviral agent |
Utilizado para | Treatment of mild to moderate COVID-19 disease in adults |
También llamado | Lagevrio® |
Disponible como | Cápsulas |
Molnupiravir is an antiviral agent that works by combining with viral RNA to stop the virus particles from replicating. If a virus can't replicate it won't be able to infect other cells in the body and the infection won't spread as quickly. Molnupiravir can reduce the severity of viral infections such as COVID-19.
Molnupiravir is used for adults who have tested positive for COVID-19 and have at least one risk factor for severe disease. Taking molnupiravir as soon as possible once COVID-19 symptoms have started can lower your risk of being severely ill or requiring hospitalisation.
People at high risk of severe COVID-19 disease include those with medical conditions such as long-term heart, lung, liver, kidney or nerve problems, people with diabetes and people with weakened immune systems.
Before taking molnupiravir capsules
Some medicines are not suitable for people with certain conditions, and sometimes a medicine may only be used if extra care is taken. For these reasons, before you start taking molnupiravir it is important that your doctor knows:
Si está embarazada, esperando un bebé o en período de lactancia.
Si alguna vez ha tenido una reacción alérgica a un medicamento.
Si está tomando otros medicamentos. Esto incluye cualquier medicamento que esté tomando y que pueda adquirirse sin receta, así como medicamentos a base de plantas y complementarios.
Seguir leyendo
How to take molnupiravir capsules
Before you start this treatment, read the manufacturer's printed information leaflet from inside your pack. The manufacturer's leaflet will give you more information about molnupiravir and a full list of side-effects which you may experience from taking it.
The usual dose of molnupiravir is four capsules (800 mg) taken every twelve hours for five days. Make sure you complete the course even if you are feeling better.
Swallow the capsules whole with a drink of water. Do not open, crush or chew the capsules.
It is not important whether you take molnupiravir capsules before or after food.
If you forget to take a dose, take it as soon as you remember unless it is nearly time for your next dose. In which case, leave out the forgotten dose and take your next dose when it is due. Do not take two doses together to make up for a missed dose.
Aproveche al máximo su tratamiento
Treatment with molnupiravir should be started within the first five days of COVID-19 symptoms or as soon as possible after a positive COVID-19 test result.
Make sure you complete the full course of treatment even if you start to feel better or do not feel unwell.
Help your body fight the infection by drinking plenty of water, eating sensibly and getting plenty of rest.
The best way to protect yourself from COVID-19 is through vaccination. Ensure your vaccinations are up to date in line with national guidance.
Seguir leyendo
Can molnupiravir cause problems?
Along with their useful effects, most medicines can cause unwanted side-effects although not everyone experiences them. The table below contains some of the most common ones associated with molnupiravir. You will find a full list in the manufacturer's information leaflet supplied with your medicine. The unwanted effects often improve as your body adjusts to the new medicine, but speak with your doctor or pharmacist if any of the following continue or become troublesome.
Common molnupiravir side-effects (affecting fewer than 1 in 10 people) | ¿Qué puedo hacer si me ocurre esto? |
Diarrea | Beber mucha agua para reponer los líquidos perdidos |
Sensación de malestar (náuseas) | Stick to simple foods. Try taking your doses with something to eat if you are not already doing so |
Mareos | No conduzca ni utilice herramientas o máquinas si se ve afectado |
Importante: En raras ocasiones este medicamento puede causar una reacción alérgica grave. Busque atención médica urgente si desarrolla una erupción cutánea roja y con picor y cualquier dificultad respiratoria, incluyendo hinchazón de la cara, labios o lengua. Tomar un antihistamínico puede ayudar a ralentizar la reacción mientras espera el tratamiento.
Si experimenta cualquier otro síntoma que considere que puede deberse a este medicamento, consulte a su médico o farmacéutico.
How to store molnupiravir capsules
Mantenga todos los medicamentos fuera del alcance y de la vista de los niños.
Almacenar en un lugar fresco y seco, lejos del calor y la luz directos.
Información importante sobre todos los medicamentos
Información importante sobre todos los medicamentos
No tome nunca más de la dosis prescrita. Si sospecha que usted u otra persona ha tomado una sobredosis de este medicamento, acuda al servicio de urgencias de su hospital. Llévese el envase, aunque esté vacío.
Este medicamento es para usted. Nunca se lo dé a otras personas aunque su enfermedad parezca ser la misma que la suya.
No guarde medicamentos caducados o que no desee. Llévelos a su farmacia local, que se encargará de eliminarlos por usted.
Si tiene cualquier duda sobre este medicamento pregunte a su farmacéutico.
Informar de los efectos secundarios de un medicamento o vacuna
Si experimenta efectos secundarios, puede notificarlos en línea a través del sitio web de la Tarjeta Amarilla.
Lecturas complementarias y referencias
- Manufacturer's PIL, Lagevrio® 200 mg hard capsules; Merck Sharp and Dohme (UK) Ltd, The electronic Medicines Compendium. Dated July 2024.
- Medicamentos BNF completa 89ª edición; Asociación Médica Británica y Real Sociedad Farmacéutica de Gran Bretaña, Londres.
Historia del artículo
La información de esta página ha sido redactada y revisada por médicos cualificados.
Fecha de la próxima revisión: 15 de diciembre de 2027
15 dic 2024 | Última versión

Pregunte, comparta, conecte.
Explore debates, formule preguntas y comparta experiencias sobre cientos de temas de salud.

¿Se encuentra mal?
Evalúe sus síntomas en línea de forma gratuita